Septerna, Inc. (NASDAQ:SEPN) Receives $43.14 Average PT from Analysts

Septerna, Inc. (NASDAQ:SEPN) has been given a consensus rating of “Moderate Buy” by the nine analysts that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $43.1429.

Several brokerages have recently commented on SEPN. Cantor Fitzgerald reissued an “overweight” rating and issued a $60.00 target price on shares of Septerna in a report on Tuesday, March 10th. Zacks Research upgraded Septerna from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Raymond James Financial began coverage on Septerna in a research note on Friday, December 19th. They issued a “strong-buy” rating and a $38.00 price objective on the stock. JPMorgan Chase & Co. increased their target price on Septerna from $34.00 to $38.00 and gave the stock an “overweight” rating in a report on Tuesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Septerna in a research note on Thursday, January 22nd.

Insider Transactions at Septerna

In other Septerna news, insider Samira Shaikhly sold 70,453 shares of the firm’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $28.10, for a total value of $1,979,729.30. Following the completion of the sale, the insider owned 793 shares in the company, valued at approximately $22,283.30. This trade represents a 98.89% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Elizabeth Bhatt sold 4,000 shares of the business’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $28.97, for a total transaction of $115,880.00. Following the completion of the transaction, the chief operating officer directly owned 174,209 shares of the company’s stock, valued at approximately $5,046,834.73. This represents a 2.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 4.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Goldman Sachs Group Inc. increased its stake in shares of Septerna by 86.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,715,129 shares of the company’s stock valued at $75,698,000 after buying an additional 1,260,409 shares during the period. First Light Asset Management LLC bought a new position in Septerna in the fourth quarter valued at about $17,308,000. Primecap Management Co. CA bought a new position in Septerna in the fourth quarter valued at about $15,225,000. Perceptive Advisors LLC acquired a new stake in Septerna in the second quarter worth about $5,723,000. Finally, VR Adviser LLC acquired a new stake in Septerna in the second quarter worth about $5,713,000.

Septerna Stock Down 3.5%

Shares of SEPN stock opened at $23.87 on Wednesday. Septerna has a 12-month low of $4.66 and a 12-month high of $32.63. The company has a market capitalization of $1.07 billion, a P/E ratio of -21.50 and a beta of 3.46. The firm has a 50-day moving average price of $26.41 and a 200 day moving average price of $24.16.

Septerna (NASDAQ:SEPN) last issued its quarterly earnings data on Monday, March 9th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.01). The firm had revenue of $24.12 million for the quarter, compared to the consensus estimate of $20.44 million. Septerna had a negative return on equity of 15.85% and a negative net margin of 106.37%. As a group, research analysts expect that Septerna will post -7.11 earnings per share for the current year.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.